Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today ...
Relmada Therapeutics Inc. (NASDAQ:RLMD) is one of the best growth stocks under $30 to buy now. On May 12, Relmada Therapeutics reported Q1 2026 results, highlighted by positive 12-month Phase 2 data ...
NDV-01 Phase 2 NMIBC results, Phase 3 mid-2026 outlook, competition, and $160m financing—read the full analysis.
Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building on ...
Relmada Therapeutics Inc. (NASDAQ:RLMD) is one of the best growth stocks under $30 to buy now. On May 12, Relmada Therapeutics reported Q1 2026 results, highlighted by positive 12-month Phase 2 data ...
View Relmada Therapeutics Inc RLMD stock quote prices, financial information, real-time forecasts, and company news from CNN.
Tonix remains rated Hold as Tonmya's commercial launch underwhelms, with Q1 2026 net product revenue at $3.7m. Read more on ...
IREN (IREN) has been added to the Russell 1000 Index as the Russell U.S. Indexes shift from an annual to a semi-annual ...
Detailed price information for Mbx Biosciences Inc (MBX-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results